Floatz logo

THK-5351

Post-stroke Dementia, Vascular Mild Cognitive Impairment

Chang Gung Memorial HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Post-stroke Dementia, Vascular Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
PITTSBURGH COMPOUND B UNLABELLED
National Taiwan University Hospital
Phase 4BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Peking University First Hospital
Phase 4BB
Risperdal
Janssen-Cilag Pty Ltd
Phase 3BB
Acetylsalicylic Acid
Peking University First Hospital
Phase 4BB
OXYCODONE HYDROCHLORIDE, HYDROCODONE-
VA Office of Research and Development
Phase 4BB

View all 42 →

Same molecule, other indications

THK-5351 is also rated in:

Alzheimer diseaseDormant
B
Indicative ·
58 / 100
View asset →
neurodegenerative diseaseDormant
B
Indicative ·
57 / 100
View asset →
vascular dementiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →